ELA026
Phase 1Small molecule
ELA026 is one of 33 small molecule programs targeting Histiocytosis. It is currently in Phase 1.
2
Indications
3
Total Trials
2
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
39 competitors in Histiocytosis
#DrugCompanyPhaseTrials
1Jakafi
IncyteApproved
Alkeran
AApotex Inc.
Approved
Leustatin
EMD SeronoApproved
Trexall
Alnylam PharmaceuticalsPhase 3
Medrol
PfizerPhase 3
Adriamycin
PfizerPhase 3
Neoral
NovartisPhase 3
Vepesid
AAvyxa
Phase 3
Atgam
NovartisPhase 3
Cellcept
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Histiocytosis1 trial
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ELA026. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- EElectra Therapeutics Inc.